Mutations in genes encoding isocitrate dehydrogenase isoforms 1 (IDH1) and 2 (IDH2) have been associated with good prognosis for patients with brain neoplasias and have been commonly found together with mutated TP53 gene. To determine the prevalence of IDH1, IDH2, and TP53 mutations and their impact on overall survival 106 glioblastoma patients were analysed. IDH1 mutations were detected in 13 and IDH2 mutation in one patient. Two homozygous samples with R132H mutation in IDH1 gene and a novel aberration K129R in IDH2 gene were found. Sixty-four percent of IDH1/IDH2 mutated tumours harboured also a mutation in TP53 gene. Genetic aberrations in TP53 were present in 37 patients. Statistical analysis of the impact of the studied factors on the overall survival showed that the mutations in IDH1/IDH2, but not the ones in TP53, were associated with longer survival. Also, the impact of age on prognosis was confirmed. This is the first comprehensive study on glioblastomas in Bulgaria. Our results suggest that IDH1/IDH2 but not TP53 mutations together with other prognostic factors such as age might be applied in clinical practice for prediction of outcome in patients with glioblastomas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017788 | PMC |
| http://dx.doi.org/10.1155/2014/654727 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clonal hematopoiesis in cardiovascular aging: Insights from the verona heart study.
Geroscience
October 2024
Department of Medicine, Section of Internal Medicine, University of Verona, 37129, Verona, Italy.
Clonal hematopoiesis of indeterminate potential (CHIP), marked by the accumulation of somatic mutations in hematopoietic stem cells, significantly elevates the risk of all-cause mortality, mainly due to cardiovascular events. Therefore, investigating this pathophysiological phenomenon is crucial for understanding cardiovascular aging and enhancing both health span and lifespan. In the present study, we examined samples of subjects enrolled within the angiographically controlled Verona Heart Study (VHS), which provides a robust model for cardiovascular aging, particularly regarding coronary artery disease (CAD).
View Article and Find Full Text PDFContemporary Management of Acute Myeloid Leukemia: A Review.
JAMA Oncol
October 2024
Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Article Synopsis
- Acute myeloid leukemia (AML) is a complex blood cancer with a higher incidence among those over 65, leading to serious health issues including bone marrow failure.
- The disease is characterized by various genetic alterations which affect treatment response and prognosis, with significant progress in incorporating molecular data for better targeted therapies.
- Recent advancements include the use of molecularly targeted inhibitors and combinations with hypomethylating agents that have improved treatment outcomes, especially for older patients.
Extent of Resection Thresholds in Molecular Subgroups of Newly Diagnosed Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Neurosurgery
October 2024
Vivian L. Smith Department of Neurosurgery, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston , Texas , USA.
Background And Objectives: Maximizing the extent of resection (EOR) improves outcomes in glioblastoma (GBM). However, previous GBM studies have not addressed the EOR impact in molecular subgroups beyond IDH1/IDH2 status. In the current article, we evaluate whether EOR confers a benefit in all GBM subtypes or only in particular molecular subgroups.
View Article and Find Full Text PDFA comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
Int J Lab Hematol
August 2024
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Introduction: The classic Philadelphia chromosome-negative myeloproliferative neoplasms (Ph (-) MPNs), have variable potential for progression to the blast phase (MPN-BP) of the disease. Except initiated by distinct driver mutations, MPN-BP frequently carry similar genetic abnormalities defining acute myeloid leukemia myelodysplasia-related (AML-MR). Because of dissimilar initial pathogenesis, MPN-BP and AML-MR are retained under different disease categories.
View Article and Find Full Text PDFPatterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
Haematologica
July 2024
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Article Synopsis
- The study focuses on the progression patterns of low-risk myelodysplastic syndrome (MDS) in a cohort of 1,914 patients, categorizing them into four distinct groups based on their disease progression.
- Key risk factors identified for progression include male gender, low blood cell counts, high bone marrow blasts, and certain genetic mutations, with specific mutations such as SRSF2 correlating with a higher risk of transformation to acute myeloid leukemia (AML).
- Notably, about 13.1% of patients with stable low-risk MDS died within two years of diagnosis, often due to complications related to cytopenia, highlighting the importance of understanding disease progression to improve treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!